Val(8)GLP-1 peptide

Val(8)GLP-1 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-HADGTYTVDVSTYLQDQAAKDFVSWLKSGRA-OH

H-His-Ala-Asp-Gly-Thr-Tyr-Thr-Val-Asp-Val-Ser-Thr-Tyr-Leu-Gln-Asp-Gln-Ala-Ala-Lys-Asp-Phe-Val-Ser-Trp-Leu-Lys-Ser-Gly-Arg-Ala-OH

31

95.36%

C₁₅₂H₂₂₉N₄₁O₅₀

3430.67

Synthetic

Powder

Val(8)GLP-1 is an enzyme-resistant analogue of the incretin hormone glucagon-like peptide 1 originally developed to treat diabetes in a mouse model of Alzheimer's disease that expresses mutated amyloid precursor protein (APP) and presenilin-1. Val(8)GLP-1 crosses the blood-brain barrier when administered via intraperitoneal injection. Val(8)GLP-1 protected LTP in 9- and 18-month-old Alzheimer's disease mice when given for 3 weeks at 25 nmol/kg intraperitoneally.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Gengler S, McClean PL, McCurtin R, Gault VA, Hölscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging. 2012 Feb;33(2):265-76. doi: 10.1016/j.neurobiolaging.2010.02.014. Epub 2010 Mar 31. PMID: 20359773.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.